Skip to main content
Supplement ScienceSupplementScience

CBD Dosage Guide

Evidence:Emerging
·

This content is for informational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary — consult your healthcare provider before starting any supplement. Full disclaimer

General Dosage

25-150mg daily for anxiety; 50-200mg for sleep. Start low (25mg) and titrate up gradually.

Maximum dose: 600mg/day has been used in clinical research without serious adverse effects (higher doses used in epilepsy under medical supervision)

Dosage Recommendations

General recommendation: 25-150mg daily for anxiety; 50-200mg for sleep. Start low (25mg) and titrate up gradually.

Timing: For anxiety: sublingual oil held under tongue 60-90 seconds, morning and/or afternoon. For sleep: 30-60 minutes before bed. • Take with food for best absorption.

Dosage by Condition

Anxiety
25-150mg daily, can divide into 2-3 dosesEmerging
Sleep support
50-200mg, 30-60 minutes before bedEmerging
Acute anxiety (public speaking)
300mg single dose, 90 minutes beforeEmerging

Upper limit: 600mg/day has been used in clinical research without serious adverse effects (higher doses used in epilepsy under medical supervision)

Timing & Absorption

For anxiety: sublingual oil held under tongue 60-90 seconds, morning and/or afternoon. For sleep: 30-60 minutes before bed.

Best taken with food for optimal absorption.

Full CBD Guide

References

  1. Case reportShannon S, Lewis N, Lee H, Hughes S (2019). Cannabidiol in anxiety and sleep: a large case series. Permanente Journal. DOI PubMed
  2. RCTLinares IM, Zuardi AW, Pereira LC, et al. (2019). Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Brazilian Journal of Psychiatry. DOI PubMed
  3. RCTZuardi AW, Cosme RA, Graeff FG, Guimarães FS (1993). Effects of ipsapirone and cannabidiol on human experimental anxiety. Journal of Psychopharmacology. DOI PubMed
  4. ReviewBlessing EM, Steenkamp MM, Manzanares J, Marmar CR (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. DOI PubMed
  5. Meta-analysisHan K, Wang JY, Wang PY, Peng YC (2024). Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis.. Psychiatry research. DOI PubMed
  6. Lo LA, Christiansen AL, Strickland JC, Pistawka CA, et al. (2024). Does acute cannabidiol (CBD) use impair performance? A meta-analysis and comparison with placebo and delta-9-tetrahydrocannabinol (THC).. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. DOI PubMed
  7. Freeman TP, Craft S, Wilson J, Stylianou S, et al. (2021). Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis.. Addiction (Abingdon, England). DOI PubMed
Show 5 more references
  1. Dos Santos MC, da Silva AMP, da Vitória Santos do Nascimento M, da Silva TMS, et al. (2026). The Influence of CBD and THC on Hepatic Enzymes of the Human Cytochrome P450 Complex Family: A Systematic Literature Review.. European journal of drug metabolism and pharmacokinetics. DOI PubMed
  2. Duan S, Liu M, An Z, Zhong Z, et al. (2026). Unlocking the potential: Cannabidiol (CBD) as a promising anti-tumor agent.. Phytomedicine : international journal of phytotherapy and phytopharmacology. DOI PubMed
  3. Gras M, Bearden D, West J, Nabbout R (2024). Efficacy of anti-seizure medications and alternative therapies (ketogenic diet, CBD, and quinidine) in KCNT1-related epilepsy: A systematic review.. Epilepsia open. DOI PubMed
  4. Aderinto N, Olatunji G, Kokori E, Ajayi YI, et al. (2024). The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials.. European journal of medical research. DOI PubMed
  5. Hindelang P, Scharinger A, Richling E, Walch SG, et al. (2022). Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.. Frontiers in bioscience (Landmark edition). DOI PubMed